Conference Evaluates Microbicides for HIV Prevention
By Rachel Walden • February 25, 2008
Please note: This entry -- originally posted at Our Bodies, Our Blog -- has not been updated since the publication date listed above.
An early report from the conference notes that tenofovir gel, a vaginal microbicide that incorporates an antiretroviral drug (such as those used in HIV treatment), has passed safety trials for daily use. The next step in research will be to study whether this gel is effective in reducing HIV infection. Another release from the conference provides preliminary safety findings on a rectal microbicide using an investigational drug.
One recent setback in microbicide research was the three-year Carraguard trial, which demonstrated the safety of the seaweed-derived product, but found that it did not significantly reduce HIV infection risk. However, it's not unusual for drug research to suffer many disappointing trials before hitting on a product that truly works. The Population Council's Peter Donaldson noted, “The trial has contributed significantly to the field’s body of knowledge regarding product development, trial design, and women’s and their partners’ willingness to use a vaginal gel consistently."
Related information:
0 Response